BioMarin Pharmaceutical Inc (BMRN) stock
Close on Nov 11, 2026Market cap $11.29BP/E 153.5Yield –
BioMarin Pharmaceutical Inc grew revenue 11.2% to $3.41B over the twelve months to Jun 30, 2026. Operating income fell 80.8% to $149.26M, moving the operating margin from 25.3% to 4.4%. Free cash flow was $738.18M, up 6.2% from a year earlier. At the latest close the market valued the company at $11.29B, 153.5 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $11.29B
- P/E ratio
- 153.5
- Price to sales
- 3.31
- Price to book
- 1.79
- Dividend yield
- –
- Free cash flow yield
- 6.54%
Fundamentals
- Revenue
- $3.41B
- Net income
- $72.97M
- EPS, diluted
- $0.38
- Free cash flow
- $738.18M
- Book value per share
- $32.51
- Diluted shares
- 194M
Trading
- Next earnings
- Feb 22, 2027 (estimated, after the close)
- Previous close
- $57.13
- Open
- $57.10
- Day's range
- $56.91 – $58.38
- Volume
- 1,658,731
- Average volume (20 days)
- 2,578,238
- Index membership
- S&P MidCap 400 (since Aug 2024), Russell 1000, Russell 3000
- Beta (5 years)
- 0.59
- 52-week range
- $49.26 – $70.98
- RSI (14 days)
- 54.6
- Volatility (1 year)
- 35.5%
- Relative volume
- 0.77×
- WACC
- 6.6%
Index membership is inferred from the holdings of funds that track each index (IJH, SPMD, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2009, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | BMRN | S&P 500 | Difference | BMRN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +6.5% | -2.4% | +8.9 pts | ||
| 3 months | -16.1% | -1.2% | −15.0 pts | ||
| Year to date | -1.9% | +12.3% | −14.1 pts | ||
| 1 year | +6.2% | +12.4% | −6.3 pts | ||
| 3 years | -30.5% | +78.8% | −109.4 pts | -11.4% | +21.4% |
| 5 years | -28.4% | +75.2% | −103.5 pts | -6.5% | +11.9% |
| 10 years | -36.2% | +311.1% | −347.3 pts | -4.4% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases BioMarin Pharmaceutical filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- News
- News
About BioMarin Pharmaceutical
Pharmaceutical Preparations
BioMarin Pharmaceutical Inc. develops and commercializes therapies targeting serious genetic conditions and rare diseases. The biotechnology company organizes its commercial operations into two core business units: Skeletal Conditions and Enzyme Therapies. Key commercial products include VOXZOGO for achondroplasia, alongside enzyme replacement treatments such as VIMIZIM, NAGLAZYME, PALYNZIQ, ALDURAZYME, BRINEURA, and KUVAN. Its customer base consists of specialty pharmacies, hospitals, non-U.S. government entities, pharmaceutical wholesalers, and authorized international distributors, with Sanofi acting as the exclusive distributor and customer for ALDURAZYME.
Company profile, executives and historyBioMarin Pharmaceutical stock: common questions
What is BioMarin Pharmaceutical's stock price?
BMRN closed at $58.33 on Nov 11, 2026, up 2.10% on the day. Over the past 52 weeks it traded between $49.26 and $70.98.
What is BioMarin Pharmaceutical's market cap?
BioMarin Pharmaceutical was worth $11.29B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is BMRN's P/E ratio?
BMRN trades at 153.5 times earnings, based on diluted earnings per share of $0.38 over the twelve months to Jun 30, 2026.
How much revenue does BioMarin Pharmaceutical make?
BioMarin Pharmaceutical reported revenue of $3.41B for the twelve months to Jun 30, 2026, up 11.2% from a year earlier.
Does BioMarin Pharmaceutical pay a dividend?
No. BioMarin Pharmaceutical has not paid a cash dividend over the last twelve months.
When does BioMarin Pharmaceutical report earnings next?
BioMarin Pharmaceutical is expected to report Q4 FY2026 results on Feb 22, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has BMRN stock performed over the past year?
Including dividends, BMRN returned +6.2% over the past year, against +12.4% for the S&P 500.
How many BMRN shares are sold short?
14M shares were sold short at the latest FINRA report, 7.33% of the float, or 5.8 days of average trading volume.
Who are BioMarin Pharmaceutical's competitors?
Companies most similar to BioMarin Pharmaceutical by business, industry and size include SRPT, UTHR, JAZZ, INSM, ACAD.
See a number that looks wrong?